C4 Therapeutics platform for discovering targeted protein degraders.
Competing Products
C4 Therapeutics
C4 Therapeutics, a US biotech firm, innovates early-stage therapies to treat cancer and neurological diseases.
Founded
2015C4 Therapeutics, a US biotech firm, innovates early-stage therapies to treat cancer and neurological diseases.
C4 Therapeutics, founded in Watertown, Massachusetts, is a biotechnology company dedicated to developing novel early-stage therapies aimed at eliminating disease-causing proteins. Their core mission is to transform lives by targeting and degrading proteins responsible for cancer, neurological, and other diseases. The company leverages Targeted Protein Degradation (TPD) science to create a new generation of medicines that offer innovative treatment options for patients.
Notable figures associated with C4 Therapeutics include leading scientists and industry experts who contribute to its pioneering research. The company has garnered significant investment from prominent biotech investors, underscoring its potential impact. Key achievements include advancing multiple therapeutic candidates into clinical development, demonstrating the promise of TPD in treating complex diseases. Overall, C4 Therapeutics is making substantial strides in the biotech industry, with a focus on transforming disease treatment paradigms.
Companies similar to C4 Therapeutics include Beactica Therapeutics, CAMP4 Therapeutics, Arvinas and Differentiated Therapeutics.
C4 Therapeutics was founded in 2015.
C4 Therapeutics' headquarters is located in Cambridge, MA, US.
C4 Therapeutics' most recent funding round was for $25M (USD) in May 2023.
As of May 30, 2023, C4 Therapeutics has disclosed funding of $298.8M (USD). Undisclosed round amounts are excluded.
C4 Therapeutics has 146 employees as of Feb 6, 2024.
Differentiated Therapeutics
dxtherapeutics.com